提炼复杂性以推进心脏组织工程学。
Distilling complexity to advance cardiac tissue engineering.
作者信息
Ogle Brenda M, Bursac Nenad, Domian Ibrahim, Huang Ngan F, Menasché Philippe, Murry Charles E, Pruitt Beth, Radisic Milica, Wu Joseph C, Wu Sean M, Zhang Jianyi, Zimmermann Wolfram-Hubertus, Vunjak-Novakovic Gordana
机构信息
Department of Biomedical Engineering, Stem Cell Institute, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
出版信息
Sci Transl Med. 2016 Jun 8;8(342):342ps13. doi: 10.1126/scitranslmed.aad2304.
Abstract
The promise of cardiac tissue engineering is in the ability to recapitulate in vitro the functional aspects of a healthy heart and disease pathology as well as to design replacement muscle for clinical therapy. Parts of this promise have been realized; others have not. In a meeting of scientists in this field, five central challenges or "big questions" were articulated that, if addressed, could substantially advance the current state of the art in modeling heart disease and realizing heart repair.
摘要
心脏组织工程的前景在于能够在体外重现健康心脏的功能方面和疾病病理学，以及设计用于临床治疗的替代肌肉。这一前景的部分内容已经实现；其他部分尚未实现。在该领域科学家的一次会议上，明确提出了五个核心挑战或“重大问题”，如果能够解决这些问题，将极大地推动目前在心脏病建模和心脏修复方面的技术水平。
相似文献
1
Distilling complexity to advance cardiac tissue engineering.提炼复杂性以推进心脏组织工程学。
Sci Transl Med. 2016 Jun 8;8(342):342ps13. doi: 10.1126/scitranslmed.aad2304.
2
Heart muscle engineering: an update on cardiac muscle replacement therapy.心肌工程学：心肌替代疗法的最新进展。
Cardiovasc Res. 2006 Aug 1;71(3):419-29. doi: 10.1016/j.cardiores.2006.03.023. Epub 2006 Apr 7.
3
Vascularisation to improve translational potential of tissue engineering systems for cardiac repair.血管化以提高用于心脏修复的组织工程系统的转化潜力。
Int J Biochem Cell Biol. 2014 Nov;56:38-46. doi: 10.1016/j.biocel.2014.10.020. Epub 2014 Oct 23.
4
Strategies and Challenges to Myocardial Replacement Therapy.心肌替代疗法的策略与挑战
Stem Cells Transl Med. 2016 Apr;5(4):410-6. doi: 10.5966/sctm.2015-0288. Epub 2016 Mar 1.
5
Cell sheet transplantation for heart tissue repair.细胞片层移植用于心脏组织修复。
J Control Release. 2013 Aug 10;169(3):336-40. doi: 10.1016/j.jconrel.2013.03.003. Epub 2013 Mar 14.
6
Engineering Cardiac Muscle Tissue: A Maturating Field of Research.工程化心肌组织：一个不断成熟的研究领域。
Circ Res. 2017 Apr 28;120(9):1487-1500. doi: 10.1161/CIRCRESAHA.117.310738.
7
Cardiac tissue engineering: from matrix design to the engineering of bionic hearts.心脏组织工程：从基质设计到仿生心脏工程
Regen Med. 2017 Apr;12(3):275-284. doi: 10.2217/rme-2016-0150. Epub 2017 May 12.
8
Current state of the art in myocardial tissue engineering.心肌组织工程的当前技术水平。
Tissue Eng. 2007 Aug;13(8):1825-36. doi: 10.1089/ten.2006.0110.
9
Cardiac tissue engineering: a clinical perspective.心脏组织工程：临床视角
Future Cardiol. 2007 Jul;3(4):435-45. doi: 10.2217/14796678.3.4.435.
10
Engineering the heart piece by piece: state of the art in cardiac tissue engineering.逐片构建心脏：心脏组织工程的现状
Regen Med. 2007 Mar;2(2):125-44. doi: 10.2217/17460751.2.2.125.
引用本文的文献
1
Living Nanofiber-Enabled Cardiac Patches for Myocardial Injury.用于心肌损伤的具有活性纳米纤维的心脏贴片
JACC Basic Transl Sci. 2025 Feb;10(2):227-240. doi: 10.1016/j.jacbts.2024.06.010. Epub 2024 Sep 4.
2
Injectable hydrogel with miR-222-engineered extracellular vesicles ameliorates myocardial ischemic reperfusion injury via mechanotransduction.含有经miR-222工程改造的细胞外囊泡的可注射水凝胶通过机械转导减轻心肌缺血再灌注损伤。
Cell Rep Med. 2025 Mar 18;6(3):101987. doi: 10.1016/j.xcrm.2025.101987. Epub 2025 Mar 3.
3
3D-Printed Myocardium-Specific Structure Enhances Maturation and Therapeutic Efficacy of Engineered Heart Tissue in Myocardial Infarction.3D打印心肌特异性结构增强心肌梗死中工程心脏组织的成熟度和治疗效果。
Adv Sci (Weinh). 2025 Mar;12(10):e2409871. doi: 10.1002/advs.202409871. Epub 2025 Jan 22.
4
Advancing Human iPSC-Derived Cardiomyocyte Hypoxia Resistance for Cardiac Regenerative Therapies through a Systematic Assessment of In Vitro Conditioning.通过系统评估体外预处理提高人诱导多能干细胞衍生心肌细胞的缺氧抗性用于心脏再生疗法。
Int J Mol Sci. 2024 Sep 5;25(17):9627. doi: 10.3390/ijms25179627.
5
Influence of Remodeled ECM and Co-culture with iPSC-Derived Cardiac Fibroblasts on the Mechanical Function of Micropatterned iPSC-Derived Cardiomyocytes.细胞外基质重构和诱导多能干细胞来源的心肌成纤维细胞共培养对微图案化诱导多能干细胞来源心肌细胞机械功能的影响。
Cardiovasc Eng Technol. 2024 Jun;15(3):264-278. doi: 10.1007/s13239-024-00711-8. Epub 2024 Mar 6.
6
An Intrinsically Magnetic Epicardial Patch for Rapid Vascular Reconstruction and Drug Delivery.一种用于快速血管重建和药物输送的内禀磁性心外膜贴片。
Adv Sci (Weinh). 2023 Dec;10(36):e2303033. doi: 10.1002/advs.202303033. Epub 2023 Nov 14.
7
Advances in the design, generation, and application of tissue-engineered myocardial equivalents.组织工程心肌替代物在设计、生成及应用方面的进展
Front Bioeng Biotechnol. 2023 Sep 22;11:1247572. doi: 10.3389/fbioe.2023.1247572. eCollection 2023.
8
Patterned Arteriole-Scale Vessels Enhance Engraftment, Perfusion, and Vessel Branching Hierarchy of Engineered Human Myocardium for Heart Regeneration.模式化的微动脉-微血管分级结构增强了工程化人心肌的植入、灌注和血管分支结构，有助于心脏再生。
Cells. 2023 Jun 23;12(13):1698. doi: 10.3390/cells12131698.
9
Leaf-venation-directed cellular alignment for macroscale cardiac constructs with tissue-like functionalities.叶脉导向的宏观心脏构建体的细胞取向以实现类似组织的功能。
Nat Commun. 2023 Apr 12;14(1):2077. doi: 10.1038/s41467-023-37716-1.
10
Micropatterned fibrin scaffolds increase cardiomyocyte alignment and contractility for the fabrication of engineered myocardial tissue.微图案化纤维蛋白支架可增加心肌细胞的定向排列和收缩力，从而用于构建工程化心肌组织。
J Biomed Mater Res A. 2023 Sep;111(9):1309-1321. doi: 10.1002/jbm.a.37530. Epub 2023 Mar 18.
本文引用的文献
1
Autonomous beating rate adaptation in human stem cell-derived cardiomyocytes.人干细胞衍生心肌细胞的自主搏动率适应性
Nat Commun. 2016 Jan 19;7:10312. doi: 10.1038/ncomms10312.
2
An integrated statistical model for enhanced murine cardiomyocyte differentiation via optimized engagement of 3D extracellular matrices.一种通过优化三维细胞外基质的作用来增强小鼠心肌细胞分化的综合统计模型。
Sci Rep. 2015 Dec 21;5:18705. doi: 10.1038/srep18705.
3
Contractility of single cardiomyocytes differentiated from pluripotent stem cells depends on physiological shape and substrate stiffness.源自多能干细胞的单个心肌细胞的收缩性取决于生理形状和底物硬度。
Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12705-10. doi: 10.1073/pnas.1508073112. Epub 2015 Sep 28.
4
HEART DISEASE. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy.心脏病。诱导多能干细胞中的肌联蛋白突变将肌节功能不全定义为扩张型心肌病的一个病因。
Science. 2015 Aug 28;349(6251):982-6. doi: 10.1126/science.aaa5458.
5
Enhanced Electrical Integration of Engineered Human Myocardium via Intramyocardial versus Epicardial Delivery in Infarcted Rat Hearts.通过心肌内注射与心外膜注射增强梗死大鼠心脏中工程化人心肌的电整合
PLoS One. 2015 Jul 10;10(7):e0131446. doi: 10.1371/journal.pone.0131446. eCollection 2015.
6
Inhibition of β-catenin signaling respecifies anterior-like endothelium into beating human cardiomyocytes.β-连环蛋白信号通路的抑制将前体样内皮细胞重编程为跳动的人类心肌细胞。
Development. 2015 Sep 15;142(18):3198-209. doi: 10.1242/dev.117010. Epub 2015 Jul 7.
7
Hurdles to clinical translation of human induced pluripotent stem cells.人类诱导多能干细胞临床转化面临的障碍。
J Clin Invest. 2015 Jul 1;125(7):2551-7. doi: 10.1172/JCI80575.
8
A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).藻酸盐水凝胶与标准药物治疗的前瞻性比较，以确定对晚期心力衰竭患者功能能力和临床结局的影响（AUGMENT-HF试验）。
Eur Heart J. 2015 Sep 7;36(34):2297-309. doi: 10.1093/eurheartj/ehv259. Epub 2015 Jun 16.
9
Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report.人胚胎干细胞来源的心肌祖细胞治疗严重心力衰竭：首例临床病例报告。
Eur Heart J. 2015 Aug 7;36(30):2011-7. doi: 10.1093/eurheartj/ehv189. Epub 2015 May 19.
10
Human iPSC-based cardiac microphysiological system for drug screening applications.用于药物筛选应用的基于人诱导多能干细胞的心脏微生理系统。
Sci Rep. 2015 Mar 9;5:8883. doi: 10.1038/srep08883.
Zotero 插件